Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Risk Assessment generated by a regulatory process
(RA)
last updated: 07 Aug 2019
EPA staff assessment report on application APP202371 - To import and release a genetically modified live-attenuated vaccine (IMOJEV®) to protect humans against Japanese encephalitis.
EN
10 Apr 2019
-
Competent National Authority:Environmental Protection Authority ()Private Bag 63002Wellington,
6140, New ZealandPhone: +64 (0)4 474 5591,Fax: +64 (0)4 914 0433,Email: neworganisms@epa.govt.nz,
-
Imojev (Japanese Encephalitis Chimeric Virus Vaccine; JE-CV)| Sanofi-Aventis New Zealand Limited | Modified viral epitopes
- APP202371 Staff Assessment Report [ English ]
EN
Loading...
